Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00136 ...
Drug Name Calcitriol
Molecular Weight 416.6365
Molecular Formula C27H44O3
CAS Number 32222-06-3
SMILES C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
External Links
DRUGBANK DB00136
T3DB T3D2692
PubChem Compound 5280453
PDR 1685
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 5.0 - 5.0 - DRUGBANK
Melting Point 113.5 ℃ 113-114 ℃ Uskokovic, M.R., Narwid, T.A., lacobelli, J.A. and Baggiolini, E.; U.S. Patent 3,993,675; November 23, 1976; assigned to Hoffmann-La Roche, Inc.

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 70.6 % 70.6±5.8 % PO, oral; normal,healthy; Male, men; DRUGBANK
Bioavailability 72.2 % 72.2±4.8 % PO, oral; RD, renal impairment, Renal disease，including uremia; Male, men; RD, renal impairment, Renal disease，including uremia ↑ ; DRUGBANK
Bioavailability 61.0 % ~61 % PO, oral; The Pharmacological Basis of Therapeutics
Bioavailability 67.0 % ~67 % Intraperitoneal, IP; The Pharmacological Basis of Therapeutics
C Max 0.0600 ng/ml 60.0±4.4 pg/ml Oral single dose; DRUGBANK
C Max 0.0900 ng/ml ~90 pg/ml PO, oral; The Pharmacological Basis of Therapeutics
C Max 0.11 ng/ml ~105 pg/ml Intraperitoneal, IP; The Pharmacological Basis of Therapeutics
C Max 0.46 ng/ml ~460 pg/ml intravenous injection, IV; The Pharmacological Basis of Therapeutics
T Max 2.0 h 2 h Oral single dose; DRUGBANK
T Max 4.5 h 3-6 h Oral single dose; DRUGBANK
T Max 4.5 h 3-6 h PO, oral; The Pharmacological Basis of Therapeutics
T Max 2.5 h 2-3 h Intraperitoneal, IP; The Pharmacological Basis of Therapeutics
Clearance 1.4 L/h 23.5±4.34 ml/min Total clearance; normal,healthy; Male, men; DRUGBANK
Clearance 0.61 L/h 10.1±1.35 ml/min Total clearance; RD, renal impairment, Renal disease，including uremia; Male, men; DRUGBANK
Clearance 0.0153 L/h/kg 15.3 ml/h/kg pediatric patients; DRUGBANK
Clearance 0.0258 L/h/kg 0.43±0.04 ml/min/kg young; patients; The Pharmacological Basis of Therapeutics
Clearance 0.0186 L/h/kg 0.31 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 0.49 L/kg 0.49±0.14 L/kg intravenous injection, IV; normal,healthy; DRUGBANK
Volume of Distribution 0.27 L/kg 0.27±0.06 L/kg intravenous injection, IV; RD, renal impairment, Renal disease，including uremia; Male, men; DRUGBANK
Volume of Distribution 0.25 L/kg 0.25 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 6.5 h 5-8 h elimination half-life; Oral single dose; DRUGBANK
Half-life 16.5 h 16.5±3.1 h young; peritoneal dialysis; Children ↑ ; The Pharmacological Basis of Therapeutics
Half-life 6.5 h 5-8 h normal,healthy; adults; The Pharmacological Basis of Therapeutics
Half-life 27.0 h 27±12 h PO, oral; The Pharmacological Basis of Therapeutics
Half-life 77760.0 h 2-16 year Children; The Pharmacological Basis of Therapeutics
Half-life 11.0 h 11 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 620.0 mg/kg 620.0 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 5.0 mg/kg >5 mg/kg Intraperitoneal, IP; Rattus, Rat; DRUGBANK
Toxicity LD50 0.62 mg/kg 620.0 ug/kg PO, oral; Rattus, Rat; T3DB
Toxicity LD50 5.0 mg/kg >5 mg/kg Intraperitoneal, IP; Rattus, Rat; T3DB
Eliminate Route 27.0 % ~27 % Faeces excretion; normal,healthy; DRUGBANK
Eliminate Route 7.0 % ~7 % Urinary excretion; normal,healthy; DRUGBANK
Eliminate Route 16.0 % 16 % Urinary excretion; intravenous injection, IV; DRUGBANK
Eliminate Route 49.0 % 49 % Faeces excretion; intravenous injection, IV; DRUGBANK
Eliminate Route 10.0 % <10 % Urinary excretion; young; peritoneal dialysis; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 99.9 % ~99.9 % DRUGBANK
Protein Binding 99.9 % 99.9 % young; peritoneal dialysis; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for neonates 0.00025 mg/day 0.25 mcg/day PO, oral Vectical calcitriol PDR
Max dose for adults 28571.4285714286 mg/day 200 g/week skin/dermal Vectical calcitriol PDR
Max dose for geriatric 28571.4285714286 mg/day 200 g/week skin/dermal Vectical calcitriol PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1